For COPD, can electronic health record data predict 90-day post hospitalization mortality — and thereby serve as a risk stratification tool?
In patients with asthma, benralizumab is associated with substantial improvements in total scores on the St. George’s Respiratory Questionnaire.
Children with an acute exacerbation of asthma were randomly assigned to receive a single tablet of montelukast or placebo.
Despite the potential for adverse events, long-term use of oral corticosteroid medications is common among patients with poor asthma control.
Asthma appeared to be associated with lower mortality in patients admitted to the hospital with myocardial infarction.
Dupilumab significantly reduced severe asthma exacerbations in patients with oral corticosteroid-dependent severe asthma with and without early improvements in lung function.
Irrespective of the type and number of background controller therapies, mepolizumab consistently reduced the annual rate of exacerbations in severe eosinophilic asthma compared with placebo.
Better asthma control in children can be achieved by either increasing inhaled corticosteroid dose or by switching to a combination of inhaled corticosteroid plus long-acting beta agonist with similar treatment outcomes.